STA
GILD icon

Smith Thornton Advisors’s Gilead Sciences GILD Stock Holding History

Smith Thornton Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,658
Closed -$298K – 137
2025
Q1 		$298K Sell
2,658
-34
-1% -$3.51K 0.19% 109
2024
Q4 		$249K Buy
2,692
+1
+0% +$90 0.16% 123
2024
Q3 		$226K Buy
+2,691
New +$205K 0.15% 124

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Smith Thornton Advisors's GILD Position: Q2 2025 in Review

Smith Thornton Advisors sold out of Gilead Sciences (GILD) in Q2 2025, closing a stake of 2,658 shares — an estimated $298K sold.

Smith Thornton Advisors first reported a position in GILD in Q3 2024 and held it in 3 quarters. The position peaked at $298K in Q1 2025. 2,023 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

  • Smith Thornton Advisors reported no remaining Gilead Sciences position as of Q2 2025 after selling out during the quarter.
  • Smith Thornton Advisors sold 2,658 Gilead Sciences shares in Q2 2025, an estimated $298K.
  • Smith Thornton Advisors first reported a position in Gilead Sciences in Q3 2024 and held it in 3 quarters.
  • Smith Thornton Advisors's Gilead Sciences position peaked at $298K in Q1 2025.
  • 2,023 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on Smith Thornton Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.